Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase&#160;2 BLAZE-4 Trial.

bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) - Eli Lilly

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

Xevudy (sotrovimab) - GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/38291279

Amanda Peppercorn; Dipak R Patel; Lisa MacPherson; Russell M Nichols; Wendy W Yeh

Jan 31, 2024